Structure-function analysis of naturally occurring apolipoprotein A-I L144R, A164S and L178P mutants provides insight on their role on HDL levels and cardiovascular risk
- 1 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cellular and Molecular Life Sciences
- Vol. 78 (4), 1523-1544
- https://doi.org/10.1007/s00018-020-03583-y
Abstract
Naturally occurring point mutations in apolipoprotein A-I (apoA-I), the major protein component of high-density lipoprotein (HDL), may affect plasma HDL-cholesterol levels and cardiovascular risk. Here, we evaluated the effect of human apoA-I mutations L144R (associated with low HDL-cholesterol), L178P (associated with low HDL-cholesterol and increased cardiovascular risk) and A164S (associated with increased cardiovascular risk and mortality without low HDL-cholesterol) on the structural integrity and functions of lipid-free and lipoprotein-associated apoA-I in an effort to explain the phenotypes of subjects carrying these mutations. All three mutants, in lipid-free form, presented structural and thermodynamic aberrations, with apoA-I[L178P] presenting the greatest thermodynamic destabilization. Additionally, apoA-I[L178P] displayed reduced ABCA1-mediated cholesterol efflux capacity. When in reconstituted HDL (rHDL), apoA-I[L144R] and apoA-I[L178P] were more thermodynamically destabilized compared to wild-type apoA-I, both displayed reduced SR-BI-mediated cholesterol efflux capacity and apoA-I[L144R] showed severe LCAT activation defect. ApoA-I[A164S] was thermodynamically unaffected when in rHDL, but exhibited a series of functional defects. Specifically, it had reduced ABCG1-mediated cholesterol and 7-ketocholesterol efflux capacity, failed to reduce ROS formation in endothelial cells and had reduced capacity to induce endothelial cell migration. Mechanistically, the latter was due to decreased capacity of rHDL-apoA-I[A164S] to activate Akt kinase possibly by interacting with endothelial LOX-1 receptor. The impaired capacity of rHDL-apoA-I[A164S] to preserve endothelial function may be related to the increased cardiovascular risk for this mutation. Overall, our structure-function analysis of L144R, A164S and L178P apoA-I mutants provides insights on how HDL-cholesterol levels and/or atheroprotective properties of apoA-I/HDL are impaired in carriers of these mutations.Funding Information
- Operational Programme “Competitiveness, Entrepreneurship and Innovation” (MIS 5002691)
- Operational Programme “Competitiveness, Entrepreneurship and Innovation” (MIS 5002550)
- Operational Programme "Competitiveness, Entrepreneurship and Innovation" (MIS 5002755)
- Fondation Leducq
This publication has 49 references indexed in Scilit:
- Effect of apoA-I Mutations in the Capacity of Reconstituted HDL to Promote ABCG1-Mediated Cholesterol EffluxPLOS ONE, 2013
- Functional Characterization of Newly-Discovered Mutations in Human SR-BIPLOS ONE, 2012
- Molecular mechanisms of vascular effects of High‐density lipoprotein: alterations in cardiovascular diseaseEMBO Molecular Medicine, 2012
- Crystal Structure of C-terminal Truncated Apolipoprotein A-I Reveals the Assembly of High Density Lipoprotein (HDL) by DimerizationJournal of Biological Chemistry, 2011
- Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery diseaseJCI Insight, 2011
- Characterization of antioxidant/anti-inflammatory properties and apoA-I-containing subpopulations of HDL from family subjects with monogenic low HDL disordersClinica Chimica Acta; International Journal of Clinical Chemistry, 2011
- Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasmaNature Structural & Molecular Biology, 2011
- ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol dietJCI Insight, 2008
- Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizesProceedings of the National Academy of Sciences of the United States of America, 2008
- Interaction of an apolipoprotein (apoLP-alanine) with phosphatidylcholineBiochemistry, 1973